Clonogenic survival assays in A549 cells revealed that shRNA-mediated UFL1 inhibition sensitized cancer cells to bleomycin treatment (Figure 8A) and mitotic spread assays showed that UFL1 depletion resulted in an increase of aberrant mitotic chromosomes (Figure 8B and C), while re-expression of a shRNA-resistant form of UFL1 rescued this defect (Figure 8A–C). Here, UFL1 is linked to cancer.